Company / Depreciation & Amortization
Fulcrum Therapeutics, Inc. Depreciation & Amortization History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$1.4M
FY2025
5-year range
$1.4M / $2.5M
FY2021-FY2025
Trend
-12.7%
vs FY2024
Sector context
#113 of 168
Health Care
What the data says
At $1M, Fulcrum Therapeutics, Inc.'s depreciation & amortization ranks #56 of 168 in the Health Care sector. Depreciation & Amortization has declined for 4 consecutive years, from $3M in FY2021 to $1M in FY2025.
Based on SEC 10-K filings.
$1M in FY2025 with a 5-year CAGR of -10.2%.
Improved from $2M to $1M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- -16.8%
- 5-Year CAGR
- -10.2%
- 10-Year CAGR
- -
Sector benchmark
#56 of 168 in Health CareTop 33% of 168This company $1.4M Sector average $212.9M
▼
-99.3% below sector average
Key checks
Key Insights
- Fulcrum Therapeutics, Inc.'s depreciation & amortization has declined for 4 consecutive years.
- 5-year CAGR of -10.2%, indicating a declining trend.
- In FY2025, depreciation & amortization decreased 12.7% year-over-year.
- Ranks #113 out of 168 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 8.44 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.4M | -12.7% |
| FY2024 | $1.6M | -26.7% |
| FY2023 | $2.2M | -10.0% |
| FY2022 | $2.4M | -4.0% |
| FY2021 | $2.5M | +5.7% |
| FY2020 | $2.4M | +15.9% |
| FY2019 | $2.1M | +52.6% |
| FY2018 | $1.3M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026